Want to see AU:BIT full AI Analyst Report?
BIT Stock Chart & Stats
AU$0.01
<AU$0.01(6.25%)
At close: 4:00 PM EST
AU$0.01
<AU$0.01(6.25%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.11
Previous CloseN/A
Volume463.29K
Average Volume (3M)1.60M
Market Cap
AU$5.57M
Enterprise ValueAU$1.64M
Total Cash (Recent Filing)AU$1.64M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,785,205,000
10 Day Avg. Volume3,265,462
30 Day Avg. Volume1,601,469
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)3.63
Price to Sales (P/S)1.10
P/FCF Ratio-3.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Debt LevelsA low-debt balance sheet reduces financial risk, providing Biotron with greater flexibility to invest in R&D and strategic initiatives without the burden of high interest expenses.
Strategic AcquisitionThe acquisition of Sedarex Limited enhances Biotron's product pipeline with a late-stage clinical asset, potentially accelerating growth and diversification in the antiviral and neuroscience fields.
Management StrengthThe appointment of Dr. Paul Kasian, with extensive experience in life sciences, strengthens Biotron's governance and strategic direction, potentially improving its business development capabilities.
Bears Say
Negative Cash FlowPersistent negative cash flow indicates ongoing reliance on external funding, which could limit Biotron's ability to sustain operations and invest in growth without raising additional capital.
Volatile RevenueVolatile revenue streams can hinder Biotron's ability to plan long-term investments and may affect investor confidence, impacting the company's ability to secure funding and partnerships.
Continued LossesOngoing losses reflect challenges in achieving profitability, which may strain Biotron's financial resources and limit its capacity to invest in R&D and market expansion.
Biotron News
BIT FAQ
What was Biotron Limited’s price range in the past 12 months?
Biotron Limited lowest share price was <AU$0.01 and its highest was AU$0.11 in the past 12 months.
What is Biotron Limited’s market cap?
Biotron Limited’s market cap is AU$5.57M.
When is Biotron Limited’s upcoming earnings report date?
Biotron Limited’s upcoming earnings report date is Aug 21, 2026 which is in 37 days.
How were Biotron Limited’s earnings last quarter?
Biotron Limited released its earnings results on Feb 26, 2026. The company reported -AU$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.001.
Is Biotron Limited overvalued?
According to Wall Street analysts Biotron Limited’s price is currently Overvalued.
Does Biotron Limited pay dividends?
Biotron Limited does not currently pay dividends.
What is Biotron Limited’s EPS estimate?
Biotron Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biotron Limited have?
Biotron Limited has 2,785,205,000 shares outstanding.
What happened to Biotron Limited’s price movement after its last earnings report?
Biotron Limited reported an EPS of -AU$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -8.333%.
Which hedge fund is a major shareholder of Biotron Limited?
Currently, no hedge funds are holding shares in AU:BIT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biotron Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Neutral
AU:BIT Sentiment 50%
Sector Average 67%
Sector Average 67%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
-119.12%
Trailing 12-Months
Asset Growth
332.38%
Trailing 12-Months
Company Description
Biotron Limited
Biotron Limited is an Australian biotechnology firm dedicated to the creation and market introduction of small molecule therapies designed to combat a range of viral illnesses. Its flagship antiviral compound, BIT225, is currently undergoing Phase II clinical evaluations for addressing infections caused by SARS-CoV-2, HIV-1, and the hepatitis C virus. Established in 1999, the company operates from its main office in Sydney, Australia.
Starpharma Holdings Limited
―
Immuron Limited
―
Bio-Gene Technology Ltd.
―
Biome Australia Ltd
―
Recce Pharmaceuticals Ltd.
―
Options Prices
Currently, No data available
---